SCHEMBL908501

SCHEMBL908501

CC1CN(c2ccccc2F)N=C1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ROCK1 Q13464 1/20 0.38
SCN9A Q15858 1/20 0.36
PI4KA P42356 1/20 0.36
PI4K2B Q8TCG2 1/20 0.36
PI4K2A Q9BTU6 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
NOTUM Q6P988 1/20 0.34
ADORA1 P30542 1/20 0.34
GRM2 Q14416 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL908503 0.81 ROCK1 (0.40) ALDH1A1ROCK1NOTUMSMN1; SMN2MAOB
SCHEMBL7719928 0.76 L3MBTL1 (0.40) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL908132 0.72 HSD11B1 (0.40) MAPTKDM4EROCK1SMN1; SMN2
SCHEMBL11063972 0.72 ALOX5 (0.42) MEN1KMT2API4KAPI4K2BPI4K2A
SCHEMBL907698 0.68 ALOX5 (0.45) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL10846355 0.66 HTR3E (0.44) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL17110621 0.64 MEN1 (0.45) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL18966917 0.64 MEN1 (0.45) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL2249111 0.62 NOTUM (0.48) ALDH1A1KDM4EGLATDP1SCN9A
SCHEMBL2246683 0.62 NOTUM (0.48) ALDH1A1KDM4EGLATDP1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 US claimed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 EP claimed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 WO claimed
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 US disclosed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 EP disclosed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases DAO, DDO, MAOA MEN1 4442/4885KMT2A 1334/4885ALDH1A1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.